![Cbd Vs Hemp Gummies: Which Is Right For Your Wellness Routine? [Tz8JKLqMk37]](https://cedclinic.com/wp-content/uploads/2026/07/ced-pexels-5021600-150x150.jpg "Cbd Vs Hemp Gummies: Which Is Right For Your Wellness Routine? [Tz8JKLqMk37] 24")
Cancer Incidence Among Users of Glucagon‑Like Peptide‑1 Receptor Agonists
A study involving over 106,000 patients found that GLP-1RA use was associated with a significantly lower risk of liver and pancreatic cancer compared to insulin.
Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuing GLP-1s
Stopping GLP-1 receptor agonists leads to substantial weight regain and reverses cardiometabolic benefits within a year. Early discontinuers face elevated cardiovascular risks.
GLP-1 Receptor Agonists and NAION
GLP-1 receptor agonists likely increase NAION risk approximately twofold, but this rare event does not outweigh their cardiovascular and metabolic benefits for most patients.
GLP-1 Receptor Agonists as a Novel Solution for Antipsychotic-Induced Weight Gain
GLP-1RAs show promise in reducing antipsychotic-induced weight gain without worsening psychiatric symptoms, offering a new approach for SPMI patients.
GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality
GLP-1 receptor agonists are associated with a statistically significant reduction in all-cause mortality for cancer patients with type 2 diabetes. This study highlights the potential benefits of GLP-1RAs in oncology settings.
Real-World Alcohol Use Disorder Outcomes in PatientsWith Concurrent Metabolic Dy
A recent study shows that GLP-1 receptor agonists are associated with a 45% lower rate of one-year AUD relapse compared to naltrexone in patients with concurrent metabolic dysfunction.